Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Sandoz Group AG (SDZNY) Q1 2026 Sales/Trading Call Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| PS Peter Sigismondi Ramirez Asset Management, Inc. | 109,038 | $4.57M | $8.65M | $4.08M | 89.17% |
| RAC Robert A. Crowley Crowley Wealth Management Inc. | 52 | $2,106 | $4,125.16 | $2,019.42 | 95.89% |
| Specialty Retail Industry | Consumer Discretionary Sector | Richard Saynor CEO | OTCQX Exchange | 799926100 CUSIP |
| CH Country | 22,049 Employees | 14 Apr 2026 Last Dividend | - Last Split | - IPO Date |
Sandoz Group AG is a global leader in the development, manufacture, and marketing of generic pharmaceuticals and biosimilars. Established in 1886, the company has its headquarters in Basel, Switzerland. Sandoz operates globally, offering a wide range of therapeutic solutions aimed at improving patient outcomes. Its mission revolves around making high-quality medicines accessible to people worldwide, leveraging its extensive experience and innovation in the pharmaceutical sector.